Pulsion targets US for growth
This article was originally published in Clinica
German company Pulsion Medical Systems, which makes diagnostic, monitoring and treatment management systems, is to increase its share capital by E786,900 ($780,290) to E8.7m in order to fund an expansion of international sales. "We will use the new capital to see our three innovative products through into markets around the world even faster, with special attention to the most exciting market for Pulsion, the US," said CEO Dr Ulrich Pfeiffer. The company has concrete plans for expansion in the US, but has no specific details for growth in any other country at present, a spokesperson told Clinica.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.